NYSE · MED
Consumer Cyclical · Personal Products & Services
$11.48
Down-$0.04 (-0.35%)
Updated Aug 15, 2026, 1:06 AM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
MED closed at $11.48 after 20 trading sessions, up 11.89% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 13, 2026 | $11.56 | $11.80 | $11.46 | $11.48 | 89.81K |
| Aug 12, 2026 | $11.66 | $11.77 | $11.52 | $11.59 | 117.55K |
| Aug 11, 2026 | $11.99 | $12.05 | $11.59 | $11.65 | 77.98K |
| Aug 10, 2026 | $12.55 | $12.7799 | $12.00 | $12.09 | 112.09K |
| Aug 7, 2026 | $12.23 | $12.84 | $12.185 | $12.62 | 140.5K |
| Aug 6, 2026 | $12.42 | $12.47 | $11.66 | $12.12 | 338.84K |
| Aug 5, 2026 | $13.14 | $13.36 | $12.23 | $12.28 | 347.58K |
| Aug 4, 2026 | $12.03 | $13.45 | $11.95 | $13.08 | 908.34K |
| Aug 3, 2026 | $9.77 | $10.13 | $9.68 | $9.74 | 250.77K |
| Jul 31, 2026 | $9.86 | $9.95 | $9.6339 | $9.83 | 103.36K |
| Jul 30, 2026 | $9.60 | $9.97 | $9.60 | $9.91 | 120.61K |
| Jul 29, 2026 | $9.67 | $9.79 | $9.52 | $9.64 | 128.48K |
| Jul 28, 2026 | $9.86 | $10.00 | $9.65 | $9.75 | 98.16K |
| Jul 27, 2026 | $9.63 | $9.98 | $9.495 | $9.91 | 152.25K |
| Jul 24, 2026 | $9.44 | $9.70 | $9.39 | $9.68 | 207.49K |
| Jul 23, 2026 | $9.76 | $9.78 | $9.39 | $9.45 | 262.69K |
| Jul 22, 2026 | $10.51 | $10.69 | $9.76 | $9.76 | 262.11K |
| Jul 21, 2026 | $10.29 | $10.53 | $10.27 | $10.52 | 156.69K |
| Jul 20, 2026 | $10.29 | $10.42 | $10.11 | $10.38 | 158.58K |
| Jul 17, 2026 | $10.50 | $10.67 | $10.24 | $10.26 | 165.28K |
The latest Smart Investors Daily articles mentioning MED.
MED research
Company profile and research snapshot.
Medifast Inc is a old health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA, which provides people with a simple, yet comprehensive approach to address obesity and support a healthy life. OPTAVIA provides unparalleled coaching support along with community, tailored nutrition and healthy habits, and empowers people to master their weight loss journey through each stage of life. The company has access to GLP-1 medications where clinically appropriate. Medifast remains committed to its mission of offering Lifelong Transformation, Making a Healthy Lifestyle Second Nature.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Feb 19, 2026 | Stephens & Co. | Equal-Weight | — |
| Feb 19, 2025 | DA Davidson | Neutral | — |
| Nov 5, 2024 | DA Davidson | Neutral | — |
| Jul 22, 2024 | DA Davidson | Underperform | — |
| Jun 5, 2024 | DA Davidson | Underperform | — |
No generated briefing is available yet.
Finnhub · May 18, 2026
BALTIMORE, MD - Client experiences and peer - reviewed research are two pillars of evidence that, at their best, reinforce each other. The former reflects what people live while the latter confirms...
SeekingAlpha · May 13, 2026
Cost-cutting initiatives, asset sales, and a positive operating cash flow position Medifast for potential profitability by Q4 2026. Read why MED is a Strong Buy.
SeekingAlpha · May 12, 2026
Medifast has continued to report concerning financials. A shrinking coach network lowers revenues, and costs remain too high. See why MED stock is a Hold.
Fintel · Feb 25, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning MED.
